Impact of Nucleic Acid Amplification Test on Clinical Outcomes in Patients with Infection.

A nucleic acid amplification test (NAAT) is recommended to determine whether or not patients have a infection (CDI) when the glutamate dehydrogenase activity assay is positive and the rapid membrane enzyme immunoassays for toxins is negative. In our hospital, a NAAT was introduced to diagnose CDI precisely in April 2020. This study aimed to investigate the impact of a NAAT on the clinical outcomes in patients with CDI at our hospital. Seventy-one patients diagnosed with CDI between April 2017 and March 2022 were included in our study. Patients with CDI were divided into two groups: before (pre-NAAT) and after (post-NAAT) the introduction of NAAT. The clinical outcome was compared between the two groups. Of the 71 patients with CDI, 41 were sorted into the pre-NAAT group and 30 into the post-NAAT group. The clinical cure rate was significantly higher in the post-NAAT group compared to the pre-NAAT group (76.7% vs. 48.8%, = 0.018). In the multivariable analysis, the clinical cure was significantly associated with the introduction of NAAT ( = 0.022). Our findings suggest that the introduction of NAAT can improve the clinical outcomes in CDI patients.